Nitroglycerin is a nitrate vasodilator indicated for relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. (1)

• At the onset of an attack, administer one tablet under the tongue or buccal pouch. One additional tablet may be administered every 5 minutes as needed. No more than 3 total tablets are recommended within a 15 minute period. (2)
• If chest pain persists after three tablets, seek prompt medical attention. (2)
• May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack. (2)

Sublingual tablets, 0.3 mg; 0.4 mg; 0.6 mg. (3)

• Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1)
• Severe anemia. (4.2)
• Increased intracranial pressure. (4.3)
• Hypersensitivity to nitroglycerin or to other nitrates or nitrites or any excipient. (4.4)
• Circulatory failure and shock. (4.5)

• Tolerance: Excessive use may lead to tolerance. (5.1)
• Hypotension: Severe hypotension may occur. (5.2)

Most common adverse reactions occurring at a frequency greater than 2% are headache, dizziness and paresthesia. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Greenstone LLC Professional information Services at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Ergotamine: Increased bioavailability of ergotamine. Avoid concomitant use. (7.2)